Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents
The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies—including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)—be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies.
- Front Matter
- Summary
- 1 Introduction
- 2 Selection or Development of an Animal Model
- 3 Generation and Characterization of Aerosolized Agents
- 4 Dosimetry Considerations
- 5 Experimental Design
- 6 Resource Issues
- References
- About the Authors
- Appendix A: Public Workshop Agenda and Biographical Information About the Speakers